Millennium Pharmaceuticals, Inc. (MLNM)

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)

An SI Board Since February 1997

Posts	SubjectMarks	Bans	Symbol
3044	135	0	MLNM

Emcee: icanpickem	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
1994	<i>Millennium's goal, says CEO Mark Levin, is to have a "balanced	RCMac	-	12/31/2003
1993	Transcriptional signature of histone deacetylase inhibition in multiple myeloma:	Icebrg	-	12/30/2003
1992	Lehman approach really beats me: Velcade is great, blah, blah, blah,... MLNM is	hmpa	-	12/24/2003
1991	Lehman believes that MLNM could break even in 2005 on improved Velcade outlook,	Area51	-	12/24/2003
1990	It would take deep pockets to cover MLNM's market cap plus a takeover premiu	tom pope	-	12/22/2003
1989	On the heels of the PFE acquisition of ESPR,MLNM getting some rumor movement: F	manny t	-	12/22/2003
1988	Millennium Initiates Phase I Clinical Trial of MLN3897 Monday December 22, 8:07	Icebrg	-	12/22/2003
1987	MLNM and several select biotech stocks gained over 4% for the week. Biotechnolog	blackmerlin	-	12/20/2003
1986	XOMA and Millennium Announce Initiation of Phase I Clinical Trial of MLN2222 --	nigel bates	-	12/18/2003
1985	Sales, THANK YOU SO MUCH for posting your communication with FDA. Erick, 3 year	Miljenko Zuanic	-	12/18/2003
1984	I am confused perhaps about the fda answer- it sounds as if the generic competit	Madharry	-	12/17/2003
1983	Orphan status precludes marketing by the competitor into an indication (as per l	hmpa	-	12/17/2003
1982	T is different than all other drugs. Once CELG has approval for MM to go with it	Biomaven	-	12/17/2003
1981	Why wouldn't the generic company use the same pathway CELG already took - ap	hmpa	-	12/17/2003
1980	Fascinating discussion w/ FDA, sales, tnks. Did any one other than me think tha	quidditch	-	12/17/2003
1979	<I> Though they might grant you some options at an attractive strike...<	software salesperson	-	12/17/2003
1978	<i>I have placed a call to sepr mgmt. to offer my services on estorra at t	nigel bates	-	12/17/2003
1977	Thanks, sales. Personally I don't see T's being generic or not has anyt	Biomaven	-	12/17/2003
1976	peter, miljenko, peter, Intrigued by the orphan drug issue, I emailed someone	software salesperson	-	12/17/2003
1975	That seems clear enough. I had my information from an analyst's comments on	Icebrg	-	12/17/2003
1974	Here's what CELG says in their 10-K: <i>As a result of our own applic	Biomaven	-	12/17/2003
1973	For additional indications the exclusivity provided by orphan designation is thr	Icebrg	-	12/17/2003
1972	They have 7 years exclusivity for Leprosy. Why they will again get 7 years for M	Miljenko Zuanic	-	12/16/2003
1971	<i>Due to facts that most likely than not T will go generic in 2005/6</	Biomaven	-	12/16/2003
1970	From time to time I visit yahoo MLNM board. Baronate and poorgradstudents posts	Miljenko Zuanic	-	12/16/2003

Go to reply# or date (mm/dd/yy):